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Abstract 
Rapidly expanding development and practice of gene therapy requires the availability of large quantities of high 
titer retroviral supernatants. One way to achieve high retroviral titers is through improved understanding of the 
kinetics of retroviral production and decay, and the subsequent development of improved cell culture methods. In 
the present study we investigated the effects of different operational modes on the retroviral production of the NIH 
3T3 fibroblast derived amphotropic murine retroviral producing cell line pMFG/~CRIP. Semi-continuous culture 
(exchange of 50% of medium volume dally) was found to promote cell growth and enhance retroviral production. 
The rapid medium exchange resulted in significantly larger amounts of high titer supernatants and an extended 
production phase as compared to the batch control cultures. The specific viral productivity of the pMFG/~CRIP 
cells was in the range of 10 to 40 infectious viruses produced per thousand producer cells per day. The CV-1 
African Green Monkey kidney cell line was used as the infection target. Lowering the serum level from 20% to 
10% improved retroviral production slightly. However, at lower serum levels (1%, 5% and 10% (v/v)) growth of 
the producer cell line, and thus retroviral production, was directly proportional to the serum level. The half-life of 
the virus at 37 ~ was found to be 5.5 hours. Promoting the growth of producer cell lines can improve retroviral 
vectors titers and viral production. High cell density systems that allow for rapid cell growth and waste product 
removal are likely to be used to generate high-titer retroviral supernatants. 
Introduction 
There is presently great interest in the introduction of 
new genes into primary human cells to enable gene 
therapy (Verma, 1990). These genetically transformed 
human cells have a wide potential application in clin- 
ical medicine (Bluestone, 1992). The goals are to cor- 
rect an identified genetic defect or be able to produce 
a therapeutically beneficial agent in situ. Thus, one of 
the more promising applications of tissue engineering 
is the construction of genetically altered human cells 
for transplantation and thus implementation of gene 
therapy. 
As an alternative to the delivery of doses of phar- 
macological molecules, the principle underlying gene 
therapy is to deliver a functional gene whose RNA 
or protein product will produce the desired biochemi- 
cal effect in the target cells or tissues. There are sev- 
eral potential advantages of gene therapy over clas- 
sical biochemical pharmacology. The inserted genes 
can produce extremely complex molecules, including 
DNA, RNA, and proteins, which can be extraordinar- 
ily difficult to administer and deliver themselves. The 
controlled insertion of the desired gene into specific 
target cells can control the production of gene product 
to defined tissue. Finally, gene therapy can in prin- 
ciple be permanent within an individual, as the gene 
will continue to function in the target cells and their 
progeny. The prime example of such a target cell is the 
human bone marrow stem cell. 
Thus, gene therapy has broad application 1:o 
both inherited and acquired diseases. For example, 
186 
hemoglobin abnormalities such as a and b Tha- 
lassemias or sickle cell anemia could be treated by 
the insertion of the gene coding for the globulin a 
or b or fetal globulin chain, together with regulatory 
sequences that confer high level tissue-specific expres- 
sion of these genes, into erythrocytes (Grosveld et al., 
1987; Sunshine et al., 1979). In addition to treating 
inherited enzymatic abnormalities of the hematopoi- 
eric system, stem cell gene therapy could be useful 
for protecting stem cells and their progeny from toxic 
exogenous agents such as viruses or chemotherapy. For 
example, gene transfer of DNA sequences encoding the 
TAR binding site of the HIV TAT transactivating fac- 
tor have been shown to protect T cells from speading 
infection by the HIV virus (Sullenger et al., 1990). 
Stable transfection of these sequences into hematopoi- 
etic stem cells would result in a pool of T cells, all 
arising from the stem cells, which were relatively or 
absolutely resistant to the spread of HIV. 
There are several problems that must be addressed 
and dealt with successfully to enable gene therapy. 
The first issue is to be able to insert the desired ther- 
apeutic gene into the chosen cells. Second, the gene 
must be adequately expressed in the target cells, result- 
ing in the appropriate levels of gene product. Finally 
the DNA, RNA, or protein produced must be properly 
processed by the target cells so that it is functional, i.e. 
so that gene therapy actually infers clinical therapy. To 
accomplish these goals, several methods of gene inser- 
tion into human cells in vitro have been developed. 
Presently, the major emphasis in gene therapy utilizes 
a replication-defective retrovirus as the delivery system 
(Miller, 1990). 
Unlike most other viruses which eventually cause 
lysis of recipient cells, retroviruses infect host cells 
and integrate into the host chromosomes in the form 
ofproviruses (Buffer, 1991; Larrick and Burck, 1991). 
An infectious replication-defective recombinant retro- 
viral vector is designed to have cis functions including 
the long terminal repeats (LTRs) - sequences for the 
promoter and enhancer, the packaging signal and the 
tRNA primer binding site. Three trans genes, gag, pol 
and env, are provided by the packaging cell line. In 
general, the therapeutic gene replaces the structural 
gene in the therapeutic vector. 
The first step in the infection process - the bind- 
ing of the virion to the target cell - is limited by the 
amount of retrovirus present in the supernatant used 
for infection. Thus high retrovirai titers are needed 
to improve infectivity. One way to improve the titers 
obtained from the producer cell lines is to properly 
design the culture conditions. To begin to understand 
the culture parameters which control the amount of 
virus produced and secreted, we have measured the 
kinetics of viral production of an amphotropic retrovi- 
ral producer pMFG/gCRIP and the degradation of the 
retrovirus produced. The results are reported herein. 
Materials and methods 
Cell lines and culture medium 
The amphotropic producer cell line pMFG/~CRIP was 
kindly provided by Dr. James Wilson at The Univer- 
sity of Michigan. The packaging cell line gJCR/P was 
derived from fibroblast NIH 3T3 and originally estab- 
lished by Danos and Mulligan (Danos and Mulligan, 
1988). It has two recombinant vectors pCRIPenv-, 
encoding for gag and pol, and pCRIPAMgag-, encod- 
ing for 4070A amphotropic virus genome. This pack- 
aging cell line was further transduced with plas- 
mid pMFG, consisting of LTRs, packaging signal Y 
(psi) and lacZ, and formed the amphotropic retro- 
viral producer cell line pMFG/~CRIP. The marker 
gene lacZ encodes bacterial/3-galactosidase, which 
can be easily used to stain positively infected target cell 
colonies. These cells were grown in Dulbecco's Mod- 
ified Eagle's medium (DMEM) (GIBCO, cat. no. 430- 
2800EB) supplemented with 10% fetal bovine serum 
(FBS) (GIBCO, cat. no 240-6000AJ). Various levels of 
serum were used for the study of retroviral production. 
CV-1 cells were used to titrate the virus super- 
natants, They are fibroblast-like cells from African 
Green Monkey (Cercopithecus aethiops) kidney 
(ATCC CCL 70). They were grown in DMEM sup- 
plemented with 10% (v/v) fetal bovine serum or calf 
serum. 
Both pMFG/tI, CRIP and CV-1 cells are anchorage- 
dependent cell lines. In both cases the cell passage 
procedure involved three steps; first, rinsing with Ca +2 
and Mg+2-free Hank's Balanced Salt Solution (HBSS) 
(GIBCO, cat. no. 310-4180A J); second, treatment with 
trypsin-EDTA (GIBCO, cat. no. 610-5400PE) and; 
third, neutralization with 10% serum DMEM. Cell 
suspensions then were split at a ratio of 1 to 10 and 
replated. 
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Cultivation of pMFG/~ CRIP and production of 
retroviral supernatants 
Three cultivation methods were investigated for the 
growth of the producer cell line pMFG/~CRIP and 
retroviral production: 
Batch culture with conditioning (BCWC). In this com- 
monly used approach, the producer cells were allowed 
to grow reaching 50% to 70% of confluence, and then 
the medium was totally replaced by fresh medium. 
Viral supernatants were collected after conditioning 
medium with the producer cells for 12 to 24 hours. 
We studied cell growth and viral production under this 
scenario on a daily basis. Ten six-well (Costar, 3406) 
plates were inoculated with 5 x 10 4 pMFG/~CRIP 
cells per well in 3 ml of 10% FBS DMEN. On each day 
following, one plate was used to determine cell growth 
and to produce retrovirus for 19 hours in fresh 10% 
and 20% FBS DMEM. Cells in two wells (duplicates) 
were trypsinized, removed, and counted to measure 
cell growth. Three milliliters of 10% and 20% FBS 
SMEM were added to each of the four remaining wells 
(duplicates) and viral supernatants were collected after 
about 19 hours. 
Batch culture (BC). Under this scenario, there was 
no medium replacement after inoculation 1.2 x 105 
pMFG/ffJCRIP cells were seeded in ten 85 mm tissue 
culture dishes in 10 ml of 10% CSS DMEM. One dish 
was taken down for cell counting, titration of retro- 
virus produced, and analysis of glucose, glutamine, 
and ammonium concentrations in the medium. 
Semi-continuous culture (SCC). After the producer 
cells were inoculated, a daily partial or complete 
replacement of medium was carried out over the period 
of time of incubation. Ten 85 mm tissue culture dishes 
were seeded with 1.2 x 105 pMFG/~CRIP cells per 
plate in 10 ml of 10% CSS DMEM. One plate was 
sacrificed daily for cell counting, viral titration, and 
analysis of substrates and metabolic byproducts; the 
rest of the dishes received a daily medium replacement 
of 5 ml from day 1 to day 4 but 50% from day 5 to day 
9. 
The effects of serum level were compared in a sep- 
arate experiment where the growth medium contained 
1%, 5% and 10% CSS. 
All virus preparations were filtered before use 
through 0.45 mm filters (Gelman Sciences, product no. 
4184) to remove any free producer cells in the super- 
natants and prevent in situ transfection of CV- 1 cells. 
Prior to use the filters were pretreated with appropriate 
serum-containing media (10%, v/v). 
Titration of virus 
Twenty to twenty-five thousand CV-1 cells were inocu- 
lated to each well of a six-well plate (Costar, 3406) with 
3 ml of growth media and incubated for 12 to 18 hours 
before the introduction of retrovirus. After removing 
the spent medium, 0.2 ml of virus solution was added 
into a well, plus 1.8 ml growth medium containing 
4.44 #g/ml of polybrene (Aldrich, cat. no. 10,768-9). 
After 8 to 10 hours at 37 ~ the infection medium was 
replaced by 3 ml of growth medium to support growth 
of CV-1 cells to confluence. Having been washed 
twice by Ca +2 and Mg+2-free Dulbecco's phosphate.- 
buffered saline (GIBCO, cat. no. 310-4080AJ), the 
confluent infected CV-1 cells in each well were fixed 
by 1.5 ml of 2.1% (v/v) formaldehyde (Sigma, cat. no. 
F-1635) and 0.2% (v/v) glutaraldehyde (Sigma, cat. 
no. G-6257) for five minutes. The cells were washed 
with PBS twice again. A staining solution was prepared 
by adding 50 ml of 20 mg/ml (2%) X-gal (5-Bromo-4- 
chloro-3-indolyl-/3-D-galactoside) (GIBCO BRL, cat. 
no. 5520UC) dissolved in N,N-Dimethylformamide 
(DMF) (Sigma, cat. no. D-8654) into each milimiter of 
the solution containing 5 mM K3Fe(CN)6 (Sigma, cat 
no. P-3667), 5 mM K4Fe(CN)6.3H20 (Sigma, cat. no. 
P-3289) and 2 mM MgC12 (Sigma, cat. no. M-8266) 
immediately before use. To each well, 1.5 ml of stain- 
ing solution was added and the plates were put into a 
37 ~ incubator for 8 to 12 hours. The stained positive 
(blue or green) colonies were counted and the titer of 
the retroviral solution was calculated as the number of 
colony formation units per milliliter of virus solution 
used (CFU/ml). 
To make sure that the infections were carried out 
under conditions where titers were not underestimated 
because the target cells were superinfected, a dosage 
response experiment was carried out. These results 
show a clear linear relationship between the colony 
formation unit (CFU) reading and the volume of virus 
supematant used (Figure 1 a). Thus, the infection assay 
was not performed under conditions where superinfec- 
tions occured. 
To compare the infection efficienty of the CV-1 
cells to the commonly used NIH 3T3 cells, we titrated 
the same viral supematants on CV-1 and NIH 3T3 cells 
in parallel. The results showed that the NIH 3T3 murine 
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Figure 1. (a) The dosage response of colony formation unit (CFU) 
reading. (b) The titer responses of CV-1 and NIH 3T3 ceils to a 
retroviral supernatant, produced by pMFG/~CRIP, at different dilu- 
tions. 0.2 ml of serially diluted retroviral solutions were added to 
each well of  six-well plates which were inoculated with CV-1 and 
NIH 3T3, respectively, at the level of  25,000 cells per well 10 
hours before infection. Then 1.8 ml of 10% CSS DMEM containing 
4.44% mg/ml of Polybrene was added to each well. The infection 
was carried out for 8 hours in an incubator and then the infection 
medium was replaced with fresh medium to support the cells growing 
until confluence and stained with X-Gal. 
cells have infectivities that are about 300 times higher 
than CV-1 (Figure lb). 
Analysis of glucose, lactate, glutamine, and 
ammonium 
Glucose and lactate in medium samples were measured 
with a glucose/lactate analyzer (Yellow Springs Instru- 
ments, Model 2000, Yellow Springs, OH). Glutamine 
and ammonium concentrations were analyzed with a 
L-glutamic acid kit (Boehringer Mannheim, 139092) 





















Figure 2. The growth of producer cell pMFG/~CRIP (a) and pro- 
duction of retrovirus (b) in batch culture with conditioning (10% and 
20% FBS DMEM). 
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Figure 3. Production kinetics of retrovirus in DMEM with 10% FCS. 
The concentration profile of retrovirus produced during conditioning 
with 10% FBS DMEM. 
Mannheim, 102903), and an ammonia kit (Boehringer 
Mannheim, 1112732), respectively. 
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Figure 4. Batch culture of producer cell pMFG/kOCRIP aud its retroviral production (a), and concentration profiles of glucose-lactate (b) and 
glutamine-ammonia (c). 
R e s u l t s  
Retroviral production in a batch culture with 
conditioning (BCWC) 
The pMFG/~CRIP cells grew to a maximum cell den- 
sity of about 2.1 x 104 cells/cm 2 following a short lag 
phase (Figure 2a). Unlike the parental cell line, these 
cells continued to grow after a confluent monolayer 
had been formed. Multiple cell layers were observed 
following day six of cultivation. Viral production was 
measured by a complete medium replacement at a par- 
ticular point in time and the concentration of virus was 
allowed to build up for 18 hours in the fresh medi- 
um. The viral titer increased in a linear fashion during 
the 18 hour period (Figure 3) and the cell population 
typically doubled during the viral production period. 
Viral production was active between day 2 and 
day 5, but began to decline when subconfluence was 
reached (Figure 2b). The production of retrovirus in 
the presence of 20% FBS was consistently lower them 
that in 10% FBS medium. The retroviral titers normal- 
ly achieved in BCWC mode were around 103 CFU/rrd, 
using CV-1 cells as the infection target. 
Retroviral production in batch culture (BC) 
In batch culture (BC), retroviral producer pMFG/ 
iPCRIP cells exhibited a three-day period of rapid 
growth with a maximal growth rate of about 5,0 • 
10 -2 hr -1. Then cell growth slowed and the culture 
reached a maximum cell density of about 2.8 x 104 
cells/cm 2 on the seventh day (Figure 4a). The viral 
titer increased dramatically while the cells were grow- 
ing rapidly and reached maximum level of 7.5 x 103 
CFU/ml on the fifth day. The titer increased while ~he 
cells were in stationary phase but declined dramatically 
following loss of viability. 
It should be noted that the peak in the retroviral 
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Figure 5. Semi-continuous culture (SCC) of producer cell pMFG/~CRIP and its retroviral production (a), and concentration profiles of 
glucose-lactate (b) and glutamine-ammonia (c). 
is shown in Figure 4a. Thus, there is a peak point in 
the titer curve that is quite sharp and whose timing is 
difficult to predict. Thus, production of virus of BC 
to obtain a high titer is unreliable, especially if large 
quantities of high titer supematants are needed. 
Analysis of glucose and glutamine concentrations 
showed that they were the main substrates for cell 
growth (Figure 4b and 4c). Neither of those limited 
growth; their concentrations were 17.6 mM of glucose 
and 1.24 mM of glutarnine, at the end of batch culture. 
Interestingly, both - though glutamine more signifi- 
cantly - were consumed after cessation of growth (at 
approximately 75 hours). The major metabolic byprod- 
ucts, lactate and ammonium, reached 13.8 mM and 
2 mM, respectively. 
Retroviral production in semi-continuous culture 
(scc) 
To promote cell growth and viral production, a rapid 
medium exchange protocol was used where about one 
half of the medium was exchanged on a daily basis. 
Over the first six days of culture the cell density 
increased exponentially at a maximal apparent spe- 
cific growth rate of 4.4 x 10 -2 hr -1 that is slightly 
lower than obtained in BC. The cell density reached a 
maximum of 1.04 x 105 cells/cm 2 (Figure 5a), approx- 
imately a four-fold higher cell density than in BC. Mul- 
tiple cell layers were observed. 
Neither of the major nutrients was depleted (Fig- 
ure 5c and 5d). Furthermore, the SCC leads to low- 
er concentrations of metabolic waste products. Thus, 
growth in SCC may be limited by the cell growth sur- 
face area. 
The titer of virus produced exceeded 103 CFU/ml 
on day three and was maintained at a higher level of 
8 x 103 to 103 to 104 CFU/ml from day 5 to day 7. 
Retroviral production was maintained during station- 
ary phase and most of the high titer supernatants are 
obtained during and shortly after entry into stationary 
phase. The cumulative colony formation units (CFU) 
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Figure 6. The effect of calf serum concentration on the growth 
of producer cell pMFG/~CRIP (a), retroviral productions (b) and 
cumulative retroviral production (c) in semi-continuous culture. 
Figure 5b. Further, most of this virus obtained at higher 
concentrations. 
Effects o f  serum concentration on cell growth and 
retroviral production 
To help identify limiting factor(s) in the medium, 
growth of pMFG/~I'CRIP cells and their retroviral pro- 
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duction were studied under the prolific SCC conditions 
of 50% dally medium replacement at different serum 
concentrations (1%, 5% and 10%). The dependence of 
cell growth on the serum in the medium was strong, 
Figure 6a. The cultures receiving 1%, 5% and 10% 
serum reached about 1.4 x 10 4, 6.9 x 10 4 and 1.4 
x 105 cells per square centimeter respectively. Thus, 
the final cell number obtained was proportional to the 
amount of serum used. The use of substrates and for- 
marion by byproducts also showed a similar proportion 
(Figure 7). 
Serum thus clearly contains mitrogenic stimulus 
for the pMFG/iI, CRIP cell line. The serum-contained 
factor that is responsible for the mitrogen stimulus Jis 
not known. However, it is known that Platelet Derived 
Growth Factor (PDGF) and Epidermal Growth Factor 
(EGF) support the growth of NIH 3T3 fibroblasts and 
they are thus likely candidates (Freshney et al 198"7; 
Reed, 1991). Although the cell yield is proportional 
to the amount of serum the cells were exposed to, 
pMFG/~I, CRIP cells exhibited quite similar maximal 
growth rate at all serum concentrations, Figure 6a. 
As the result of better cell growth, the cultures with 
higher serum levels showed better viral production, 
Figure 6b and 6c. The titers obtained from the 1%, 
5% and 10% serum-containing cultures were approx- 
imately proportional to the serum concentration. This 
observation suggests that the viral production is strong- 
ly promoted by cell growth. Figure 7 shows the con- 
centration profiles of glucose, lactate, glutamine, arid 
ammonia during the culture of pMFG/~t'CRIP cells 
in DMEM with different levels of calf serum supple- 
ment. The correlation of glucose and glutamine con- 
sumption and lactate and ammonium production are 
presented in Figure 8. The lactate/glocose and ammo- 
nium/glutamine yields are essentially constant in both 
SCC and BC. 
Deactivation of  retrovirus 
The stability of the retrovirus is one of the most impor- 
tant factors in the development of an optimal strategy 
for retroviral production and design of infection sys- 
tem. Retroviral sypernatants collected from the culture 
0.45 mm syringe filters and then titrated at certain tirae 
intervals. The viral supernatants were put into an incu- 
bator at 37 ~ during the course of deactivation. The 
decay of the retrovirus produced by pMFG/~CRIP at 
37 ~ is shown in Figure 9. The half-life of the virus 
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Figure 7. Concentration profiles of glucose (a), lactate (b), glutamine (c) and ammonia (d) during the semi-continuous culture of pMFG/~CRIP 
cells in DMEM with 1%, 5% and 10% calf serum supplement. 
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Figure 8. Correlation between glucose consumption and lactate formation (a), glutamine consumption and ammonia formation (b). These data 
are from the batch (BC) and semi-continuous culture (SCC) of pMFG/xI'CRIP cells in 10% calf serum supplemented DMEM. 
193 




0 ~ 0 ~  . 
0 . ~  
0 
. . . .  i . . . . . . . .  
5 1 '0 
t ( h o u r s )  
Figure 9. Stability profile of pMFG/~CRIP derived retrovirus at 
37~ 
Specific retroviral productivities 
The specific (per cell) retroviral productivity of the 
pMFG/~CRIP cell line is readily calculated from the 
growth curve and the retroviral titer as 
qv = DCvt Vt/S Xvt At 
where qv is the specific retroviral productivity (CFU 
per 103 cells per hour), Cvt is the concentration of 
virus,  Xvt is the average viable cell density per unit 
area over the period of time (At) of retroviral produc- 
tion, S/Vt is the specific surface area. The calculated 
results for qv are presented in Table 1. Based on these 
data, we estimated that the specific viral productivity 
during growth and early stationary phase is in the range 
10--40 CFU/103 cells/day, when titrated on CV-1 cells. 
The number of NIH 3T3 infective particles is expect- 
ed to be 300 times higher. The data presented here is 
too fragmented to correlate qv with specific cell para- 
meters, which is likely caused by the relatively high 
instability of the viral particles. 
Discussion 
As detailed in the Introduction, the effective transfer of 
therapeutic genes into the target cells relies on the avail- 
ability of retroviral vector preparations of sufficiently 
high titers. We have studied the kinetics of the retro- 
viral vector producer cell line pMFG/~CRIP in order 
to find an efficient way to produce high titer retrovi- 
ral supernatants in large quantities. Three operational 
modes, i.e., batch culture with conditioning (BCWC), 
batch culture (BC), as well as semi-continuous culture 
(SCC), were investigated. Based on this study we can 
draw several important conclusions about the growth, 
metabolism, and viral production of the pMFG/~CRIP 
producer cell line. 
The primary conclusion from the present results 
is that the production of retrovirus from the 
pMFG/ffgCRIP cell line can be increased by promoting 
cell growth and cell density. In the batch culture, the 
accumulation of viral fiter followed cell growth closely 
and reached its maximum before cell viability started 
to decline (Figure 4). The prolonged high-titer produc- 
tion phase observed in the semi-continuous process 
(Figures 5 and 6) was evidently due to the extend- 
ed growth phase of the producer cells. For example, 
pMFG/iI~CRIP cells had an exponential phase of about 
three days in the batch culture, while in the semi- 
continuous culture in 10% CSS DMEM, the cells expe- 
rienced a six-day active growth phase. This result sup- 
ports the hypothesis that high cell density bioreactor 
systems would give high viral titer supernatants. 
A semi-continuous perfusion strategy was proven 
to be effective to improve the growth of producing cell 
line pMFG/gCRIP as well as retroviral production. 
SCC mode provided an additional supply of growth 
factors and nutrients which probably were limiting or 
not sufficient for cell growth and function, and helped 
to remove metabolic products and other inhibitory 
compounds such as lactate and ammonium ions. Com- 
pared with what was achieved in batch culture, the cell 
density in SCC mode was about 4 times as high as that 
of BC mode, indicating a better capability to support 
cell growth. Although NIH 3T3 cells are reported to 
be inhibited by ammonium ions (Visek et al., 1992), 
preliminary data from our laboratory indicates that at 
the ammonium concentration experienced here growth 
of pMFG/iPCRIP is not retarded. 
The dependence of pMFG/e/CRIP cell growth arLd 
retroviral production on serum was evident in 85 mm 
tissue culture dishes, when different concentrations 
of serum (1%, 5% and 10%) were used for medium 
replacement. The effective components of this limi- 
tation are considered most likely to be PDGF and/or 
EGF, which are considered to be necessary for the 
growth of NIH 3T3 cells. However, as demonstrated in 
the BCWC mode, 20% FBS DMEM consistently gave 
no boost of viral production. This suggests the exis- 
tence of agents in serum which inhibit or neutralize the 
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Table 1. Specific retroviral productivities calculated in different 
processes (CFU/103 pMFG/~CRIP cells/day). The virus was titrated 
on CV-1 cells 
Time Process a
(days) 1 2 3 4 5 6 7 
1 33.3 18.3 32 .0  31.7 35.1 53.4 
2 96.7 70.7 0.2 7.8 29.0 12.3 
3 37.9 23.7 10.2 15.8 225 9.9 
4 43.8 36.7 14.2 18.1 12.4 14.1 
5 26.7 10.9 29.9 21.1 5.0 15.7 
6 4.2 4.0 7.5 24.1 11.4 
7 7.5 8.1 6.0 3.0 7.9 
8 0.6 0.1 1.2 6.0 13.3 
9 8.6 6.2 2.7 











a 1 - BCWC, 10% FBS; 
2 - BCWC, 20% FBS; 
3-BC, 10% CSS; 
4 - SCC, 10% CSS; 
5 - SCC, 1% CSS; 
6 - SCC, 5% CSS; 
7 - SCC, 10% CSS. 
viruses produced resulting in lower titer supernatants 
(Aaronson and Stephenson, 1974; Levy et  al., 1975; 
Stephenson et  al. ,  1976). 
Viral product ivi ty and titers can be enhanced by 
improving growth conditions. Viral production in both 
growth and stationary phase have been observed, and 
undoubtedly ceases as cell viabil i ty decreases. The 
production of  infectious retrovirus particles by the pro- 
ducer cell  line pMFG/ffJCRIP depends on the appropri-  
ate expression and assembling of  their products of  the 
genes gag (viral core protein), pol  (reverse transcrip- 
tase) and env (viral envelope) into viral particles, and 
most  importantly,  the inclusion of  viral RNA into the 
viral particles. Because these viral genes are encoded 
on three separately located DNA constructs, the forma- 
tion of  viral elements may not be in the right proportion 
as required by  the composi t ion of  viral structure. One 
element  may  be the l imiting factor for the assembly of  
infectious viral particles. How the cell cycle status of  
the producer  cells affect the expression of  these genes is 
not known. Among  the virus particles produced,  some 
may have no viral RNA at all (Butler, 1991). Some 
may have no, or improperly,  translated env products 
and are therefore not  infectious (Fields et  al., 1990). 
The per  cell  productivi ty was found to be approx- 
imately a constant, at 10 to 40 CV-1 infectious viral 
particles per  thousand producing cells per  day (Table 
1). However,  as shown in Figure lb ,  the susceptibility 
of  NIH 3T3 ceils is 300 times higher than that of  CV- 1 
cells to the viruses produced by pMFG/~CRIP .  The 
reason for this difference is unknown. Both growth 
and stationary phase should be suitable for use in high 
density systems. The virus would be secreted into a 
relatively small culture volume leading to high titers. 
Although batch and semi-continuous culture modes 
are useful ways to produce retrovirus from producer  
cell lines that have growth-related viral production, an 
operational strategy can also be developed by  extend- 
ing cell growth in high cell density systems, thus pro- 
longing the viral production phase. 
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